TRANSCENTA-B (06628.HK): Gets RMB 95m first payment on CDMO asset sale
NewTimeSpace News: On 20 October 2026, Transcenta Holding Limited (stock code: 06628) said the Group has received the net after-tax first payment of RMB 95 million from the purchaser, a wholly owned subsidiary of WuXi Biologics, under the asset purchase agreement for the disposal of CDMO assets, which carries an aggregate consideration of RMB 190 million subject to the adjustment mechanism set out in the circular.
The proceeds will supplement the Group's general working capital and fund the development of its product pipeline. Staff costs and operating expenses are expected to decline in 2027 from 2026 as a result of the disposal. Handover of the CDMO assets is proceeding, and the Company expects to receive additional proceeds before the end of 2026, subject to the terms and conditions of the asset purchase agreement.
- TRANSCENTA-B (06628.HK): CLDN18.2 Antibody Patent Granted in China
- TRANSCENTA-B (06628.HK): Proposes disposal of CDMO assets for RMB 190 million to a WuXi Biologics subsidiary, focusing on innovative drug R&D as core business
- CNBM (03323.HK): expects nine-month loss of about RMB 760 million
- C ZENITH CHEM (00362.HK): Listing to Be Cancelled on 20 October
- STAR Market Integrated Circuit Companies' First-Half Net Profit Up More Than Tenfold as the "15th Five-Year Plan" for the Electronic Information Manufacturing Industry Lands; Premia China STAR50 ETF (03151.HK) Gains 20.31% Year to Date, Beating the SSE ST
